Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 in Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
CTR20191071Phase 2Active
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started May 2019; status: active.
02
Drugs
benmelstobart
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on CTR20191071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191071.